Henry Schein HSIC Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

CencoraCOR

——

Globus MedicalGMED

——

Brown & BrownBRO

——

Other financials

Income statement

See full

Revenue$3.4B+6.3%

Gross profit$1.1B+7.0%

Operating income$182.0M+4.0%

Net income$107.0M-2.7%

EPS (diluted)$0.92+4.5%

Balance sheet

See full

Cash & equivalents$138.0M+8.7%

Total debt$3.7B+17.2%

Total equity$3.3B-1.3%

Total assets$11.3B+7.9%

Cash flow

See full

Operating cash flow-$97.0M-362%

CapEx$25.0M-19.4%

Free cash flow-$122.0M-2,133%

Valuation

See full

Market cap$9.1B-0.6%

Enterprise value$12.69B+4.2%

P/E23.1×+0.5×

P/S0.7×0.0×

Profitability

See full

Gross margin31.2%-0.4pp

Operating margin4.9%-0.2pp

Net margin3%-0.3pp

FCF margin3.3%-1.0pp

Returns & leverage

See full

Return on equity12%+0.2pp

Debt / equity1.1×+0.2×

Current ratio1.4×0.0×

Where this comes from

Reported directly by Henry Schein in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Henry Schein’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Henry Schein's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Henry Schein's contingent consideration fair value adjustments?: Henry Schein (HSIC) reported contingent consideration fair value adjustments of $0 in Q1 2026.
How has Henry Schein's contingent consideration fair value adjustments changed year-over-year?: Henry Schein's contingent consideration fair value adjustments decreased by 100.0% year-over-year, from $93M to $0.